AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02077478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remifentanil and propofol administration using TCI
Study NCT02077478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remifentanil and propofol administration using MCI
Study NCT01788228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
Description: 2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.
Study NCT00601198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Patients should be treated with oxaliplatin-based chemotherapy in combination with amifostine for 12 cycles, or until unacceptable toxicity is observed or disease progression
Study NCT02261454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gum chewing
Description: 1 piece of sugarless gum three times daily to be chewed for 1 hour each time.
Study NCT00270439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: removal of omentum
Description: patients with type 2 diabetes had their omentum removed
Study NCT01153074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closure of bronchopleural fistula with Occlutech Figulla
Description: Patients with bronchopleural fistulas will be submitted to a bronchoscopic procedure to deploy the cardiac septal defect occluder in the fistula traject.
Study NCT00370071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
Study NCT02272075 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile OCT M3 scope
Study NCT02310763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06252616
Description: PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
Study NCT01932307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neck strengthening exercise program
Description: Study subjects will be introduced to a 2-minute neck strengthening exercise program and advised to follow for 10 weeks. The exercise program will include five different exercises that will strengthen the neck and stabilize the scapula. The exercises are: Chin retraction, cracking the egg, scapular clock, wall pushup and scapula retraction. Each will be completed as 3 isometric holds, 3 repetitions per set and 2 sets per exercise.
Study NCT02310763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02738827 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser treatment
Description: Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department
Study NCT02221063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thiamin fortified fish sauce (low concentration)
Description: Low concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
Study NCT00870948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
Study NCT02762578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Twice daily subcutaneous (sc, under the skin) injection.
Study NCT02762578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart
Description: Twice daily subcutaneous (sc, under the skin) injection.
Study NCT04456257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional picosecond 1,064 nm laser
Description: The parameter of laser was 8-mm spot size, 0.6 mJ/cm2, 750 ps, 10 Hz, 2 passes. The treatment was done in every 4 weeks for 4 sessions.
Study NCT00508755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait Robot
Description: gait training with the use of a gait robot
Study NCT00508755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Neuromuscular stimulation with intramuscular electrodes
Description: gait training with use of functional electrical stimulation
Study NCT01765907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU
Study NCT00833235 — intervention group
Intervention type: OTHER
Intervention: Artificial Tears
Description: Artificial tears (any brand) may be used to treat dry eye symptoms.
Study NCT04478266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amcenestrant-matching placebo
Description: Pharmaceutical form: Tablets Route of Administration: Oral
Study NCT00337467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir + Ritonavir
Description: Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks
Study NCT02520804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sterofundin
Description: sterofundin for shock patients in the first 72 hours
Study NCT02520804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: Normal saline for shock patients in the first 72 hours
Study NCT05267353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention program
Description: It was developed, along with usual care, to prevent restricted ROM in both upper body and limited general physical functioning. Patients in exercise intervention group received verbal instructions about stretching major muscles and phsical activity recommendations from a trained nurse (intervenor), and then received the booklet plus DVD.~The physical therapist who developed and adjusted this program also trained the intervenor. After verifying the intervenor has performed exercise interventions were consistent with the physical therapist, he/she was responsible for all interventions. Therefore, if pain or discomfort persists for more than an hour, the patient should inform the intervenor. The intervention group patients also received telephone follow-up from the intervenor every two weeks until the end of the intervention.
Study NCT02221063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thiamin fortified fish sauce (higher concentration)
Description: Higher concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
Study NCT02221063 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo fish sauce
Description: Fish sauce fortified only with iron, not thiamin, will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
Study NCT02761603 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Aging Practice-centered Instruction (HAPI)
Description: Sessions will include interactive activities derived from the CDC's Program to Encourage Active and Rewarding LiveS (PEARLS) and will include lectures based on health-related topics from presentations given by experts as part of the UC San Diego Stein Institute of Aging's Successful Aging project. The PEARLS Problem Solving Treatment (PST) group discussions will be facilitated by a trained instructor in order for participants to identify problems or barriers they have in engaging in healthy behaviors relevant to each of 12 topic areas (e.g. sleep, nutrition, mental health, social support, bone health, diabetes prevention, cognitive wellness, and resilience). Each session will be composed of: Successful Aging video (45 min), discussion (40 min), and identifying problem solving strategies (25 min) with a homework assignment each week, for a total of 24 hours of in-class instruction and discussion.
Study NCT02761603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi (CHI)
Description: Sessions will include expert instruction in the brief Yang-style 8-form Tai Chi meditative movements. Each class will include a 10-minute warm-up and cool-down plus 40 minutes of Tai Chi instruction and or practice, for a total of 24 hours of in-class instruction
Study NCT03907241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octanorm 16.5%
Description: Human normal immunoglobulin
Study NCT01752530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer program C8
Description: Experimental: Computer program C8 + treatment as usual: Playing a special computer program C8 40 min a day for 6 days a week for 8 weeks.
Study NCT01752530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual at the clinic
Study NCT01752530 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual at the clinic
Study NCT04869371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel injection
Description: 75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy
Study NCT04869371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin Pamoate for Injectable Suspension
Description: 15mg every 12 weeks
Study NCT04869371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate for Injectable Suspension
Description: 15mg every 12 weeks
Study NCT04869371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Acetate Tablets
Description: 5 mg oral low dose prednisone, once daily
Study NCT02209116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Qb Test
Description: Given to all participants but the results will be open or blind depending on arm allocation
Study NCT02209116 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qb Test
Description: Given to all participants but the results will be open or blind depending on arm allocation
Study NCT01937351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pantheris System
Description: Atherectomy using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries.
Study NCT02872051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBBIS mental health care and standard vocational rehabilitation
Description: Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists, and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment
Study NCT02872051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated mental health care and vocational rehabilitation
Description: Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element
Study NCT02408120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Half of total daily dose (TDD) will be given as insulin glargine and will be given once daily, at the same time of the day.~Daily insulin dose will be adjusted as follow:~* If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~* If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~* If the fasting and pre-dinner BG is >180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~* If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~* If a patient develops hypoglycemia (BG \<70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%.
Study NCT02408120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Half of total daily dose will be given as insulin aspart and in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, the dose of aspart will be held.~Daily insulin dose will be adjusted as follow:~* If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~* If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~* If the fasting and pre-dinner BG is >180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~* If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~* If a patient develops hypoglycemia (BG \<70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%.
Study NCT02408120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental insulin aspart
Description: Insulin aspart will be administered following the supplemental insulin scale protocol.~For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:~* BG >141-180 mg/dL; 2-4 units of insulin aspart~* BG between 181-220 mg/dL; 3-6 units of insulin aspart~* BG between 221-260 mg/dL; 4-8 units of insulin aspart~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG > 400 mg/dL; 8-16 units of insulin aspart~For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG > 400 mg/dL; 8-16 units of insulin aspart
Study NCT02289937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT02289937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02289937 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively
Study NCT02289937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively
Study NCT01447225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
Study NCT01447225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: administered at AUC 6
Study NCT01447225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: administered IV at 500 mg/m2
Study NCT01447225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: administered IV at 20 mg/m2 or 25 mg/m2
Study NCT01447225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: administered IV at 1000 mg/m2 or 1250 mg/m2
Study NCT01514123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-100
Description: VGX-100 will be administered by IV infusion once every week
Study NCT04478266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR439859
Description: Pharmaceutical form: Tablets Route of Administration: Oral
Study NCT04478266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
Study NCT04478266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
Study NCT04478266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Pharmaceutical form: Capsules Route of Administration: Orally
Study NCT04478266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous
Study NCT04478266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous
Study NCT04478266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole-matching placebo
Description: Pharmaceutical form: Capsules Route of Administration: Orally
Study NCT05065814 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Systemic lupus erythematosus group
Description: Demographic information of systemic lupus erythematosus who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
Study NCT05065814 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Systemic sclerosis group
Description: Demographic information of Systemic sclerosis who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.
Study NCT05065814 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy control group
Description: Healthy individuals with no chronic diseases who agreed to participate in the study and gave their consent will be included in the study.
Study NCT02866916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXL01
Description: Treatment will be administered continuously over 24h through the subcutaneous route.
Study NCT01468675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: risk assessment survey; decision support for providers for prevention based on risk
Study NCT02317588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flax Oil
Description: Participants will consume capsules containing flax oil at a dose of 4 grams of ALA per day (8 capsules a day) with a meal for 28 days (4 weeks).
Study NCT02317588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Participants will consume capsules containing fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day (8 capsules) for 28 days (4 weeks).
Study NCT00028782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanidazole
Description: Given IV
Study NCT00028782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00028782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03734042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma intrauterine infusion
Description: platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11
Study NCT02918916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: The dosage applied will be 30 Joules per site (180 Joules per muscle). Parameters are described in the attached document.
Study NCT02918916 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled.
Study NCT03653975 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT03734042 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intrauterine infusion of normal saline at day 11
Study NCT02399553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer boot intervention
Study NCT04246697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol
Description: Used for both arms, scheduled
Study NCT01186536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein supplement
Description: 40 g/day of whey protein will be consumed in 2 doses for 9 months (Study duration)
Study NCT01186536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Supplement
Description: 40 g/day of soy protein will be consumed in 2 doses for 9 months (Study duration)
Study NCT01186536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplement
Description: 40 g/day of maltodextrin will be consumed in 2 doses for 9 months (Study duration)
Study NCT00391729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks